Taurine in Peripartum Cardiomyopathy

Taurine for Early Left Ventricular Recovery in Peripartum Cardiomyopathy


Lead Sponsor: Ain Shams University

Source Ain Shams University
Brief Summary

Taurine as an adjunct for early left ventricular recovery in peripartum cardiomyopathy

Overall Status Completed
Start Date 2015-01-01
Completion Date 2020-01-01
Primary Completion Date 2019-12-01
Phase Phase 2/Phase 3
Study Type Interventional
Primary Outcome
Measure Time Frame
improvement of the left ventricular ejection fraction >10 % 1 week
Enrollment 40

Intervention Type: Drug

Intervention Name: Taurine Solution

Description: Taurine Solution

Arm Group Label: Taurine

Intervention Type: Dietary Supplement

Intervention Name: Normal Saline

Description: Normal Saline

Arm Group Label: Saline



Inclusion Criteria: - Peripartum Cardiomyopathy Exclusion Criteria: - Other identifiable cause for heart failure - low LVEF ≤ 25% - sepsis - autoimmune disease - severe chronic disease - malignancy



Minimum Age:

18 Years

Maximum Age:

40 Years

Healthy Volunteers:


Facility: Ain Shams University Maternity Hospital
Location Countries


Verification Date


Responsible Party

Type: Principal Investigator

Investigator Affiliation: Ain Shams University

Investigator Full Name: Mohamed S Sweed, MD

Investigator Title: Principal Investigator

Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Label: Taurine

Type: Experimental

Label: Saline

Type: Placebo Comparator

Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Treatment

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News